Table 3.
Univariate Analysis of PFS
| Characteristics | N | PFS (Median, Month) | P |
|---|---|---|---|
| Age (years) | 0.532 | ||
| ≤65 | 42 | 8.8 | |
| >65 | 39 | 14.7 | |
| Sex | 0.716 | ||
| Male | 37 | 8.3 | |
| Female | 44 | 14.7 | |
| Smoking | <0.001 | ||
| Ever | 22 | 6.9 | |
| Never | 59 | 14.7 | |
| EGFR | 0.007 | ||
| 19‐Del | 46 | 16.1 | |
| 21‐L858R | 35 | 7.5 | |
| ECOG | 0.675 | ||
| 0–1 | 55 | 12.4 | |
| 2–3 | 26 | 13.4 | |
| ProGRP | <0.001 | ||
| Elevated | 33 | 7.1 | |
| Normal | 48 | 16.1 | |
| CEA | 0.156 | ||
| Elevated | 60 | 12.7 | |
| Normal | 21 | 13.6 | |
| NSE | 0.001 | ||
| Elevated | 31 | 7.0 | |
| Normal | 50 | 16.1 | |
| CYFRA 21–1 | 0.112 | ||
| Elevated | 53 | 12.4 | |
| Normal | 28 | 13.1 | |
| CA72-4 | 0.240 | ||
| Elevated | 16 | 7.6 | |
| Normal | 65 | 13.1 | |
| SCC | 0.876 | ||
| Elevated | 7 | 14.7 | |
| Normal | 74 | 11.5 | |
| EGFR-TKI | 0.923 | ||
| Gefitinib | 62 | 8.8 | |
| Erlotinib | 19 | 13.6 |
Abbreviations: PFS, Progression-free survival; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group performance status; ProGRP, Pro-gastrin-releasing peptide; CEA, carcinoembryonic antigen; NSE, neuron-specific enolase; CYFRA 21–1, cytokeratin 19 fragment; CA 72–4, carbohydrate antigen 72–4; SCC, squamous cell carcinoma antigen; TKI, tyrosine kinase inhibitor.